NEXAVAR®

Drug Information Related Patent
Hold Company
BAYER HLTHCARE
Dosage and Administration
TABLET;ORAL
Specification
EQ 200MG BASE
Indication
NEXAVAR® is applicable to hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
API
SORAFENIB TOSYLATE
API Structure
Drug Patent
Patent NoExpiration Date
88779332027/12/24
97374882028/9/10
API Patent
Patent NoExpiration Date
88779332027/12/24

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top